Bifeprunox Explained

Verifiedfields:	changed
Verifiedrevid:	459978705
Iupac Name:	7-[4-(biphenyl-3-ylmethyl)piperazin-1-yl]-1,3-benzoxazol-2(3H)-one
Cas Number:	350992-10-8
Atc Prefix:	none
Chembl:	218166
Pubchem:	208951
Chemspiderid:	181044
Unii:	AP69E83Z79
C:	24
H:	23
N:	3
O:	2
Smiles:	O=C2Oc1c(cccc1N2)N5CCN(Cc4cccc(c3ccccc3)c4)CC5
Stdinchi:	1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28)
Stdinchikey:	CYGODHVAJQTCBG-UHFFFAOYSA-N

Bifeprunox (INN) (code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D₂ receptor agonism with serotonin receptor agonism.^[1] It was under development for the treatment of schizophrenia, psychosis and Parkinson's disease.^[2]

In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects.^[3] An NDA for Bifeprunox was filed with the U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007.^[4] In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."^[5]

Pharmacodynamics

Bifeprunox is an atypical antipsychotic that is a partial D2 agonist.

See also

• Aripiprazole
• Pardoprunox

Notes and References

1. Cuisiat S, Bourdiol N, Lacharme V, Newman-Tancredi A, Colpaert F, Vacher B . Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities . J. Med. Chem. . 50 . 4 . 865–76 . 2007 . 17300168 . 10.1021/jm061180b.
2. Web site: Bifeprunox . 2023-11-16 . go.drugbank.com . en.
3. Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology. 200. 3. 317–31. October 2008. 18597078. 10.1007/s00213-008-1207-7. 23291727.
4. http://www.finanznachrichten.de/nachrichten-2007-08/artikel-8796651.asp Wyeth and Solvay say FDA rejects application for antipsychotic drug bifeprunox.
5. http://www.lundbeck.com/investor/releases/ReleaseDetails/Release_1331489_EN.asp Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinued